Aurinia exploring strategic alternatives, including sale

30 June 2023

Canada-headquartered Aurinia Pharmaceuticals (Nasdaq: AUPH) saw its shares leap more than 17% to $10.77 in pre-market trading, after it said that its board of directors has initiated an exploration of strategic alternatives.

As part of this process, the board will consider a wide range of options for the company including, but not limited to, a potential sale, merger, or other strategic transaction.

Commenting on the news, SVB Securities analyst Joseph Schwartz said he has long thought of Aurinia as a potentially attractive buyout candidate, given Lupkynis (voclosporin) is its one approved asset in a large indication (lupus nephritis/LN), which could make the company an easy bolt-on acquisition by companies in the rheumatology/nephrology space.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK